Hims & Hers Health (NYSE:HIMS) CFO Oluyemi Okupe Sells 4,938 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 4,938 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $29.99, for a total value of $148,090.62. Following the transaction, the chief financial officer owned 264,117 shares of the company’s stock, valued at $7,920,868.83. This trade represents a 1.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Thursday, June 18th, Oluyemi Okupe sold 55,383 shares of Hims & Hers Health stock. The shares were sold at an average price of $35.09, for a total value of $1,943,389.47.
• On Monday, August 17th, Oluyemi Okupe sold 9,388 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.89, for a total value of $261,831.32.
• On Monday, July 6th, Oluyemi Okupe sold 7,163 shares of Hims & Hers Health stock. The stock was sold at an average price of $36.49, for a total value of $261,377.87.
• On Monday, June 22nd, Oluyemi Okupe sold 18,197 shares of Hims & Hers Health stock. The shares were sold at an average price of $34.03, for a total value of $619,243.91.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS traded up $0.86 on Thursday, hitting $31.95. The stock had a trading volume of 18,871,045 shares, compared to its average volume of 26,241,924. The firm’s 50 day moving average price is $32.17 and its 200-day moving average price is $26.05. The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93. Hims & Hers Health, Inc. has a twelve month low of $13.74 and a twelve month high of $65.30. The company has a market capitalization of $7.45 billion, a price-to-earnings ratio of -50.71 and a beta of 2.40.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). The firm had revenue of $753.21 million for the quarter, compared to analyst estimates of $698.90 million. Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The company’s revenue for the quarter was up 38.2% compared to the same quarter last year. During the same quarter last year, the business earned $0.17 EPS. On average, equities research analysts predict that Hims & Hers Health, Inc. will post -0.05 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on HIMS shares. Jefferies Financial Group set a $24.50 target price on Hims & Hers Health in a report on Tuesday, May 12th. TD Cowen raised their price target on Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a report on Tuesday, August 11th. Truist Financial lifted their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Friday, July 24th. BTIG Research reissued a “neutral” rating on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Finally, Wall Street Zen upgraded Hims & Hers Health from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Four analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $32.43.

Institutional Investors Weigh In On Hims & Hers Health

Several institutional investors have recently modified their holdings of the business. QV Investors Inc. bought a new stake in shares of Hims & Hers Health during the second quarter worth approximately $7,771,000. Kelly Lawrence W & Associates Inc. CA bought a new position in Hims & Hers Health in the second quarter valued at approximately $11,520,000. Bank of New York Mellon Corp bought a new position in Hims & Hers Health in the second quarter valued at approximately $46,220,000. Handelsbanken Fonder AB grew its holdings in Hims & Hers Health by 4.0% during the 2nd quarter. Handelsbanken Fonder AB now owns 60,000 shares of the company’s stock worth $2,080,000 after acquiring an additional 2,300 shares during the period. Finally, Valeo Financial Advisors LLC acquired a new stake in Hims & Hers Health during the 2nd quarter worth $225,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: CEO Andrew Dudum rejected the FTC’s allegations concerning data privacy, advertising, billing and subscription cancellations, arguing that the agency misunderstands Hims & Hers’ business practices. His comments may be helping ease concerns after the recent regulatory-driven selloff. Hims & Hers rejects privacy allegations
• Positive Sentiment: Analysts remain focused on Hims & Hers’ growth potential, including margin expansion and broader access to care. A recent investment thesis characterized the current margin pressure as a potential buying opportunity, while the CEO said an AI health coach could launch within roughly 12 months and potentially improve medication adherence. Hims & Hers: Buying the Margin Dip
• Neutral Sentiment: Management’s planned expansion into AI-enabled care, testosterone and peptide treatments could create new growth avenues, but these initiatives remain prospective and do not immediately resolve regulatory or profitability concerns.
• Negative Sentiment: The FTC lawsuit remains the central overhang. It alleges improper handling of private health data and potentially deceptive billing and cancellation practices. Multiple law firms, including Kaplan Fox, Berger Montague and Kessler Topaz, have announced investigations that could increase legal costs, compliance requirements and potential securities-liability exposure. Kaplan Fox investigation
• Negative Sentiment: Recent earnings showed strong revenue growth of 38.2% year over year and revenue above expectations, but the company posted a substantially larger-than-expected loss. The $0.37 adjusted loss per share versus a $0.05 consensus loss highlights investor concerns about margins and execution.
• Negative Sentiment: Several executives reported stock dispositions, including sales by the CEO, CFO and CTO. Most were nondiscretionary share withholdings or sales under Rule 10b5-1 plans to cover taxes on vested equity, limiting their value as a confidence signal but still adding a modest supply-related overhang. SEC insider transaction filing

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.